Clinical Research Directory
Browse clinical research sites, groups, and studies.
HexafluOride, a Contrast Agent for Placenta Echo-angiography
Sponsor: Centre Hospitalier Régional Metz-Thionville
Summary
The purpose of this study is to quantify the placental perfusion during the first trimester of pregnancy by 3D Doppler ultrasound angiography without a contrast agent and by ultrasound with a contrast agent: SonoVue®
Official title: Feasibility Study of the Measurement of the Placental Perfusion During the First Trimester of Pregnancy by 3D Doppler Echo-angiography With a Contrast Agent
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
55
Start Date
2016-10-12
Completion Date
2019-09-30
Last Updated
2026-06-24
Healthy Volunteers
No
Conditions
Interventions
Contrast agent: SonoVue®.
SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
Locations (2)
Chr Metz Thionville
Metz, France
CHRU de NANCY
Nancy, France